57 filings
Page 3 of 3
8-K
ucxb7vrkb5d jl2b
21 Mar 22
Departure of Directors or Certain Officers
6:32am
8-K/A
fk8ko21oj
21 Mar 22
Departure of Directors or Certain Officers
6:30am
8-K
606re13i
1 Mar 22
Departure of Directors or Certain Officers
5:07pm
8-K
909cu7zq
23 Feb 22
Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer
5:07pm
8-K
hp770 8l0
22 Feb 22
Adagio Therapeutics Announces CEO Succession Plan
7:57am
8-K
8hdgzy 16b
18 Feb 22
Departure of Directors or Certain Officers
5:29pm
8-K
x5h2vttr j8avmek
13 Jan 22
Regulation FD Disclosure
8:01am
8-K
d7zh98u505pzrxrqym
14 Dec 21
Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant
9:10am
8-K
8iaqj55 dk5sjn409g9
29 Nov 21
Regulation FD Disclosure
8:23am
8-K
ddcc5gtcfwk0e5i tbwh
22 Nov 21
Adagio Therapeutics Announces Expansion of Management Team and Board of Directors
5:04pm
8-K
i43vu21e5c 6q9xewq0
16 Nov 21
Regulation FD Disclosure
5:24pm
8-K
b0lw9impjiv 29koqu
15 Nov 21
Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results
8:08am
8-K
78p6hn 8gm
19 Oct 21
Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants
4:03pm
8-K
o2c2upib0n4vg2gcs
29 Sep 21
Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19
4:41pm
8-K
m0l03ciji
20 Sep 21
Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business
4:05pm
8-K
0ma5s
10 Sep 21
Adagio Therapeutics Announces Expansion of Patient Population in Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19
7:55am
8-K
zrxeeun678 2sf
10 Aug 21
Amendments to Articles of Incorporation or Bylaws
5:26pm